A compound medication—consisting of olanzapine (an atypical antipsychotic) and fluoxetine (a selective serotonin reuptake inhibitor)—indicated for the acute treatment of depressive episodes associated with treatment-resistant depression and bipolar i disorder in adults. Marketed under the brand name symbyax.